Opioids and insulin secretion: a new avenue to fight type 2 diabetes

HORIZON.1.1HORIZON-ERCID: 101043671
EC Contribution
€19,979
Consortium Size
1 orgs
Summary

Type 2 diabetes (T2D) and obesity are leading causes of morbidity and mortality, becoming a major burden on public health. Failure to understand their pathophysiology has frustrated efforts to develop improved therapeutic strategies. T2D and obesity are complex polygenic disorders. Genome-wide association studies have identified hundreds of loci associated with metabolic traits, but they have not led to promising new drug targets, so far. In contrast, the identification and characterization of rare mutations causing monogenic metabolic disorders have been instrumental in repositioning or developing drugs. Beyond this proof of concept, the challenge is to use genomic medicine for innovative molecules restoring impaired insulin secretion that characterizes T2D.OπO has stemmed from the old but forgotten correlation between opioids consumption and metabolic trait abnormalities. Opioids classically act through delta opioid receptor (DOP encoded by OPRD1), kappa and mu opioid receptors. Based on my preliminary data that include large-scale human functional genetics of OPRD1 mutations, my hypothesis is that DOP is a major link between opioids and metabolism in humans. More specifically, I propose that DOP and opioid signaling have a crucial direct role in insulin secretion from pancreatic β cells; making DOP a promising new drug target against T2D.In this context, I suggest four tasks in OπO: the first two tasks will decipher the role of DOP and opioid signaling in metabolism with a specific focus on islets and β cells, while the two following tasks will decipher the systemic contribution of opioids and opioid receptors to metabolism. The methodologies that I proposed are truly comprehensive and innovative as they combine preclinical animal studies (with a humanized mouse model), deep phenotyping of islets, pharmacology, multi-omic analyses, genome editing, functional genetics, genetic epidemiology (including Mendelian randomization) and clinical intervention study.

Consortium (1)

Project Results (12)

Source: CORDIS, the EU research results database.

Publications (11)
Diabetes
Diabetes· 2024DOI
Maurin L.; Marselli L.; Boissel M.; Ning L.; Boutry R.; Fernandes J.; Suleiman M.; De Luca C.; Leloire A.; Pascat V.; Toussaint B.; Amanzougarene S.; Derhourhi M.; Jorns A.; Lenzen S.; Pattou F.; Kerr-Conte J.; Canouil M.; Marchetti P.; Bonnefond A.; Froguel P.; Khamis A.
Nature Communications
Nature Communications· 2024DOI
Sarah Meulebrouck; Judith Merrheim; Gurvan Queniat; Cyril Bourouh; Mehdi Derhourhi; Mathilde Boissel; Xiaoyan Yi; Alaa Badreddine; Raphaël Boutry; Audrey Leloire; Bénédicte Toussaint; Souhila Amanzougarene; Emmanuel Vaillant; Emmanuelle Durand; Hélène Loiselle; Marlène Huyvaert; Aurélie Dechaume; Victoria Scherrer; Piero Marchetti; Beverley Balkau; Guillaume Charpentier; Sylvia Franc; Michel Marre; Ronan Roussel; Raphaël Scharfmann; Miriam Cnop; Mickaël Canouil; Morgane Baron; Philippe Froguel; Amélie Bonnefond
Pathogenic, total loss-of-function DYRK1B variants cause monogenic obesity associated with type 2 diabetes
Diabetes Care· 2024DOI
Lise Folon; Morgane Baron; Victoria Scherrer; Bénédicte Toussaint; Emmanuel Vaillant; Hélène Loiselle; Aurélie Dechaume; Frédérique De Pooter; Raphaël Boutry; Mathilde Boissel; Aboubacar Diallo; Lijiao Ning; Beverley Balkau; Guillaume Charpentier; Sylvia Franc; Michel Marre; Mehdi Derhourhi; Philippe Froguel; Amélie Bonnefond
Time-of-day-dependent variation of the human liver transcriptome and metabolome is disrupted in MASLD
JHEP Reports· 2024DOI
Manuel Johanns; Joel T. Haas; Violetta Raverdy; Jimmy Vandel; Julie Chevalier-Dubois; Loic Guille; Bruno Derudas; Benjamin Legendre; Robert Caiazzo; Helene Verkindt; Viviane Gnemmi; Emmanuelle Leteurtre; Mehdi Derhourhi; Amélie Bonnefond; Philippe Froguel; Jérôme Eeckhoute; Guillaume Lassailly; Philippe Mathurin; François Pattou; Bart Staels; Philippe Lefebvre
Trends in Endocrinology and Metabolism
Trends Endocrinol Metab· 2024DOI
Lauriane Le Collen; Philippe Froguel; Amélie Bonnefond
Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study
The Lancet Diabetes & Endocrinology· 2023DOI
Folon, Lise; Baron, Morgane; Toussaint, Bénédicte; Vaillant, Emmanuel; Boissel, Mathilde; Scherrer, Victoria; Loiselle, Hélène; Leloire, Audrey; Badreddine, Alaa; Balkau, Beverley J.; Charpentier, Guillaume; Franc, Sylvia; Marre, Michel; Aboulouard, Soulaimane; Salzet, Michel; Canouil, Mickaël; Derhourhi, Mehdi; Froguel, Philippe; Bonnefond, Amélie
European Journal of Endocrinology
European Journal of Endocrinology· 2023DOI
Blandine Gatta-Cherifi; Alexandre Laboye; Caroline Gronnier; Maud Monsaingeon-Henry; Sarah Meulebrouck; Morgane Baron; Françoise Bertin; Emilie Pupier; Sophie Cambos; Christine Poitou; Johanne Le Beyec-Le Bihan; Amélie Bonnefond
Heterozygous pathogenic variants in POMC are not responsible for monogenic obesity: Implication for MC4R agonist use
Genetics in Medicine· 2023DOI
Lauriane Le Collen; Brigitte Delemer; Christine Poitou; Martine Vaxillaire; Bénédicte Toussaint; Aurélie Dechaume; Alaa Badreddine; Mathilde Boissel; Mehdi Derhourhi; Karine Clément; Jean M. Petit; Frédéric Tran Mau-Them; Ange-Line Bruel; Christel Thauvin-Robinet; Alexandru Saveanu; Blandine Gatta Cherifi; Johanne Le Beyec-Le Bihan; Philippe Froguel; Amélie Bonnefond
Monogenic diabetes
Nature Reviews Disease Primers· 2023DOI
Amélie Bonnefond; Ranjit Unnikrishnan; Alessandro Doria; Martine Vaxillaire; Rohit N. Kulkarni; Viswanathan Mohan; Vincenzo Trischitta; Philippe Froguel
Pathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk and identify a subgroup of patients sensitive to sulfonylureas
Diabetologia· 2023DOI
Sarah Meulebrouck; Victoria Scherrer; Raphaël Boutry; Bénédicte Toussaint; Emmanuel Vaillant; Aurélie Dechaume; Hélène Loiselle; Beverley Balkau; Guillaume Charpentier; Sylvia Franc; Michel Marre; Morgane Baron; Martine Vaxillaire; Mehdi Derhourhi; Mathilde Boissel; Philippe Froguel; Amélie Bonnefond
Diabetologia
Diabetologia· 2022DOI
Bonnefond, Amélie
Deliverables (1)
Data Management Plan